Conclusion The rise of GLP-1 microdosing may help patients achieve a more targeted approach to managing the unique metabolic shifts of perimenopause and menopause
Patients starting with normal insulin sensitivity may instead notice appetite suppression as the dominant effect
Many people report that injecting into the abdomen causes more immediate or intense nausea compared to the thigh
With that in mind, here are some potential medications to discuss: Other GLP-1 receptor agonists: Ozempic belongs to a family of medications called GLP-1 medications
It has multiple actions including: potentiation of glucose-mediated insulin secretion mechanisms identified: increased -cell proliferation, resulting in an increase -cell mass (Fusco et al, 2017) stimulation of insulin biosynthesis at the translational level, helping to maintain -cell insulin stores and secretory capacity (Baggio & Drucker, 2007) because the GLP-1 effect is glucose-dependent (there is more insulin release when glucose levels are elevated, but less effect when glucose levels are normal), GLP-1 agonists have a lower risk for producing hypoglycemia compared to sulfonylureas (that chronically stimulate insulin release, independent of glucose concentration) suppression of postprandial glucagon release Evidence indicates that stimulation of pancreatic cells by GLP-1 increases their glucose sensitivity, resulting in less glucagon release at any glucose level (Baggio & Drucker, 2007)
